Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Fasted Condition Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants

NCT06502379
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD8965, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 5, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalency Study of Oxymorphone Hydrochloride 10 mg Tablets Under Fasted Conditions

NCT01210638
View directory record Official record
Conditions
Pain
Interventions
Oxymorphone
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 5, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers

NCT05024747
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
NicoDerm CQ patch (GSK Dungarvan), NicoDerm CQ (Alza)
Drug
Lead sponsor
HALEON
Industry
Eligibility
21 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Sep 5, 2026, 2:06 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants

NCT06070948
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Sep 5, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules

NCT04967443
View directory record Official record
Conditions
Hypertension, Heart Failure
Interventions
Prazosin HCl 2mg, Prazosin HCl 1 mg, Prazosin HCl 5 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 5, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.

NCT02018536
View directory record Official record
Conditions
Healthy
Interventions
GSK2336805 30 mg, GSK2336805 60 mg, GSK2336805 120 mg, TMC435 150 mg (Treatment A), GSK2336805 60 mg (Treatment B and part of Treatment C and D), TMC435 100 mg (part of Treatment C), TMC435 150 mg (part of treatment D)
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
20 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Sep 5, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02851095
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 5, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate Effect of Food and Safety of a New Formulation of Zoliflodacin

NCT03718806
View directory record Official record
Conditions
Gonorrhea
Interventions
Zoliflodacin, high calorie, high fat breakfast
Drug · Other
Lead sponsor
Drugs for Neglected Diseases
Other
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 5, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers

NCT01924676
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2015 · Synced Sep 5, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects

NCT06094738
View directory record Official record
Conditions
Healthy
Interventions
Relacorilant under fasted conditions, Relacorilant after a high-fat meal, Relacorilant after a low-fat meal
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 5, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan

NCT00969449
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Naproxen Sodium, (BAY H6689), Naprelan, (BAY H6689)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 5, 2026, 2:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg/25 mg Tablet Under Fasted Conditions

NCT01102478
View directory record Official record
Conditions
Hypertension
Interventions
losartan potassium / hydrochlorothiazide
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 5, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Donepezil Hydrochloride 10 mg Tablets Under Fed Conditions

NCT01276080
View directory record Official record
Conditions
Healthy
Interventions
Donepezil
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Sep 5, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma

NCT06205407
View directory record Official record
Conditions
Healthy Participants
Interventions
Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris, Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 5, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Bioavailability of Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting Conditions

NCT01448772
View directory record Official record
Conditions
Bioavailability
Interventions
Dronabinol Capsules, 5 mg, Dronabinol Oral Solution
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2012 · Synced Sep 5, 2026, 2:06 AM EDT
Completed Phase 1 Interventional

Study of GS-3242 in Participants With HIV-1; Substudy-05

NCT07001319
View directory record Official record
Conditions
HIV-1-infection
Interventions
GS-3242, BVY, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Bakersfield, California • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 5, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of GSK1265744 Formulations

NCT01648257
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Hepatitis
Interventions
GSK1265744 Na Salt Tablets, GSK1265744 Free Acid Nanomilled Capsules, GSK1265744 Free Acid Micronized Capsules
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 64 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Sep 5, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-017)

NCT06772818
View directory record Official record
Conditions
Healthy
Interventions
Nemtabrutinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 5, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Results available

Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas

NCT01898078
View directory record Official record
Conditions
Advanced Solid Tumors, Lymphoma
Interventions
Alisertib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
The Bronx, New York • Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Sep 5, 2026, 2:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolic Processes in Adults and Adolescents With Autism Spectrum Disorder

NCT02733120
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
stable isotope infusion
Other
Lead sponsor
Texas A&M University
Other
Eligibility
16 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 5, 2026, 2:06 AM EDT
Completed Phase 1 Interventional

Interaction With HIV Antiretroviral Agents

NCT02556268
View directory record Official record
Conditions
HIV-DDI
Interventions
Riociguat (Adempas, BAY 63-2521), ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, Antiretroviral protease inhibitor
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Orlando, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Sep 5, 2026, 2:06 AM EDT
Recruiting Phase 1 Interventional

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

NCT07403721
View directory record Official record
Conditions
Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Interventions
AMG 436
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Irvine, California • Newport Beach, California • Zion, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 5, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Two Bioanalytical Assays for Tebipenem

NCT05856747
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TBP-PI-HBr
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Creve Coeur, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 5, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma

NCT03522298
View directory record Official record
Conditions
Glioblastoma, Adult
Interventions
Paxalisib (GDC-0084)
Drug
Lead sponsor
Kazia Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Sep 5, 2026, 2:06 AM EDT